Top 5 Most Read RNS's on Vox Markets for Wednesday 31st August 2022
Episode 862, Aug 31, 2022, 06:39 AM
5. Alien Metals Limited #UFO Agreement for potential Hancock Project finance
Its wholly-owned subsidiary Iron Ore Company of Australia has entered into a mandate letter providing for an exclusive right to negotiate project funding and offtake arrangements with Anglo American.
(Click here to read the RNS)
4. Omega Diagnostics #ODX - Change of preliminary results date
Preliminary results for the year ended 31 March 2022 will be further delayed as the Company and its auditors require additional time. This work is now expected to be completed in mid-September.
(Click here to read the RNS)
3. Polarean Imaging #POLX - Half-year Report
They highlight the United States FDA acceptance of resubmission of Polarean's New Drug Application following the Complete Response Letter received in October 2021, with an established user fee goal date of 30 September 2022.
Net cash of US$22.7m as of 30 June 2022, which, based on strategic decisions, could finance the Company into 2024
(Click here to read the RNS)
2. Nanosynth Group #NNN - Successful Trial Results.
Successful trial results with Volz enable both companies to develop a standard retro-fit to media production lines, that allows for the incorporation of the Company's antiviral technology into heating, ventilation, and air conditioning ("HVAC")units.
(Click here to read the RNS)
1. Supply @ME Capital #SYME - Issue of Equity & Total Voting Rights
£3,289.79 will be received by the Company as a result of the exercise of such Open Offer Warrants.
(Click here to read the RNS)
To read any of these RNS's in full visits VoxMarkets.co.uk
Its wholly-owned subsidiary Iron Ore Company of Australia has entered into a mandate letter providing for an exclusive right to negotiate project funding and offtake arrangements with Anglo American.
(Click here to read the RNS)
4. Omega Diagnostics #ODX - Change of preliminary results date
Preliminary results for the year ended 31 March 2022 will be further delayed as the Company and its auditors require additional time. This work is now expected to be completed in mid-September.
(Click here to read the RNS)
3. Polarean Imaging #POLX - Half-year Report
They highlight the United States FDA acceptance of resubmission of Polarean's New Drug Application following the Complete Response Letter received in October 2021, with an established user fee goal date of 30 September 2022.
Net cash of US$22.7m as of 30 June 2022, which, based on strategic decisions, could finance the Company into 2024
(Click here to read the RNS)
2. Nanosynth Group #NNN - Successful Trial Results.
Successful trial results with Volz enable both companies to develop a standard retro-fit to media production lines, that allows for the incorporation of the Company's antiviral technology into heating, ventilation, and air conditioning ("HVAC")units.
(Click here to read the RNS)
1. Supply @ME Capital #SYME - Issue of Equity & Total Voting Rights
£3,289.79 will be received by the Company as a result of the exercise of such Open Offer Warrants.
(Click here to read the RNS)
To read any of these RNS's in full visits VoxMarkets.co.uk